AbbVie & UroGen Overactive Bladder Treatment Misses in Phase 2 Trial
A formulation of AbbVie’s blockbuster wrinkle treatment, acquired through its buyout of Allergan, has failed a mid-stage tr…
A formulation of AbbVie’s blockbuster wrinkle treatment, acquired through its buyout of Allergan, has failed a mid-stage tr…
Drugs designed to precisely target cancers with specific genetic signatures have changed the course of disease for many pati…
The ability to detect early signs of cancer in a patient’s blood could improve prognoses by helping doctors treat the diseas…